U.S. Markets open in 7 hrs 34 mins
S&P Futures
3,367.25+15.25(+0.45%)Dow Futures
27,835.00+171.00(+0.62%)Nasdaq Futures
11,456.25+49.00(+0.43%)
Forte Biosciences, Inc. (FBRX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
48.51+2.91 (+6.38%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 49.08 |
| Open | 48.50 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 47.85 - 50.00 |
| 52 Week Range | 13.35 - 675.00 |
| Volume | 45,416 |
| Avg. Volume | 80,332 |
| Market Cap | 543.545M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 85.00 |
- Business Wire
Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the clinical trial of FB-401 for the treatment of atopic dermatitis.
- Simply Wall St.
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Business Wire
Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the publication in Science Translational Medicine of the full results of the Phase 1/2a data for its lead product candidate, FB-401.
© 2020 Verizon Media. All rights reserved.
